Gene testing for all breast cancer patients with second primary malignancy

Tuesday, September 15, 2020

Hematology/Oncology News:

  1. Study supports multigene panel testing for all breast cancer patients with second primary cancers:

  2. Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results:


  3. Pralsetinib: Second drug for RET+ NSCLC approved in U.S.:

  4. Unexpected results in new COVID-19 ‘cytokine storm’ data:
    JAMA research letter:

You can email the show at [email protected]

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.